WO2001081319A3 - Barbituriques hypnotiques a action ultrabreve - Google Patents

Barbituriques hypnotiques a action ultrabreve Download PDF

Info

Publication number
WO2001081319A3
WO2001081319A3 PCT/US2001/013246 US0113246W WO0181319A3 WO 2001081319 A3 WO2001081319 A3 WO 2001081319A3 US 0113246 W US0113246 W US 0113246W WO 0181319 A3 WO0181319 A3 WO 0181319A3
Authority
WO
WIPO (PCT)
Prior art keywords
acting hypnotic
barbiturates
ultrashort acting
ultrashort
hypnotic barbiturates
Prior art date
Application number
PCT/US2001/013246
Other languages
English (en)
Other versions
WO2001081319A2 (fr
Inventor
Pascal Druzgala
Peter G Milner
Original Assignee
Aryx Therapeutics
Pascal Druzgala
Peter G Milner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aryx Therapeutics, Pascal Druzgala, Peter G Milner filed Critical Aryx Therapeutics
Priority to JP2001578413A priority Critical patent/JP2003531196A/ja
Priority to CA002404898A priority patent/CA2404898A1/fr
Priority to AU5723001A priority patent/AU5723001A/xx
Priority to AU2001257230A priority patent/AU2001257230B2/en
Priority to EP01930722A priority patent/EP1276728A2/fr
Publication of WO2001081319A2 publication Critical patent/WO2001081319A2/fr
Publication of WO2001081319A3 publication Critical patent/WO2001081319A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/66—Thiobarbituric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne de nouveaux composés utiles en tant que barbituriques hypnotiques à action ultrabrève. D'une manière spécifique, l'invention concerne des dérivés d'acides barbiturique et thiobarbiturique, lesquels sont rapidement métabolisés par le sang et les enzymes tissulaires de manière à former des métabolites polaires qui ne présentent pas d'activité hypnotique et sont rapidement éliminés.
PCT/US2001/013246 2000-04-24 2001-04-24 Barbituriques hypnotiques a action ultrabreve WO2001081319A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2001578413A JP2003531196A (ja) 2000-04-24 2001-04-24 超短時間作用型催眠性バルビツール酸塩
CA002404898A CA2404898A1 (fr) 2000-04-24 2001-04-24 Barbituriques hypnotiques a action ultrabreve
AU5723001A AU5723001A (en) 2000-04-24 2001-04-24 Ultrashort acting hypnotic barbiturates
AU2001257230A AU2001257230B2 (en) 2000-04-24 2001-04-24 Ultrashort acting hypnotic barbiturates
EP01930722A EP1276728A2 (fr) 2000-04-24 2001-04-24 Barbituriques hypnotiques a action ultrabreve

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19914400P 2000-04-24 2000-04-24
US60/199,144 2000-04-24

Publications (2)

Publication Number Publication Date
WO2001081319A2 WO2001081319A2 (fr) 2001-11-01
WO2001081319A3 true WO2001081319A3 (fr) 2002-05-16

Family

ID=22736404

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/013246 WO2001081319A2 (fr) 2000-04-24 2001-04-24 Barbituriques hypnotiques a action ultrabreve

Country Status (6)

Country Link
US (4) US6387914B2 (fr)
EP (1) EP1276728A2 (fr)
JP (1) JP2003531196A (fr)
AU (2) AU5723001A (fr)
CA (1) CA2404898A1 (fr)
WO (1) WO2001081319A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003531196A (ja) 2000-04-24 2003-10-21 アリックス セラピューティクス 超短時間作用型催眠性バルビツール酸塩
US7049326B2 (en) * 2000-05-12 2006-05-23 The University Of Toledo Method and compositions for temporarily incapacitating subjects
US6756047B2 (en) * 2000-05-12 2004-06-29 The University Of Toledo Method and compositions for treating persistent pulmonary hypertension using aralkyl ester soft drugs
US6750238B1 (en) 2000-05-12 2004-06-15 The University Of Toledo Aralkyl ester soft drugs
US10537061B2 (en) * 2010-02-26 2020-01-21 Cnh Industrial America Llc System and method for controlling harvest operations
WO2014014960A1 (fr) * 2012-07-16 2014-01-23 Dignity Health Traitement de l'épilepsie et de l'addiction à l'alcool au moyen de créatine
EP3193862B1 (fr) 2014-09-16 2023-10-18 Igc Pharma Ip, Llc Composition topique de cannabinoïdes pour le traitement de la douleur arthritique
WO2016118391A1 (fr) 2015-01-25 2016-07-28 India Globalization Capital, Inc. Compositions et procédés de traitement de troubles épileptiques
US10596159B2 (en) 2015-08-12 2020-03-24 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
EP3471746A4 (fr) 2016-06-15 2020-02-26 India Globalization Capital, Inc. Méthode et composition pour traiter des troubles epileptiques

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2405732A1 (de) * 1974-02-07 1975-08-21 Bayer Ag Ekto- und endoparasitenmittel
FR2300568A1 (fr) * 1975-02-17 1976-09-10 Spofa Vereinigte Pharma Werke Procede de preparation de nouveaux derives de l'acide 5-carboxyalcoyle-2-iminobarbiturique
US4634707A (en) * 1983-12-19 1987-01-06 Uniroyal Chemical Company 5-Pyrimidinecarboxamides and treatment of leukemia and tumors therewith
WO1991008191A1 (fr) * 1989-11-14 1991-06-13 Sloan-Kettering Institute For Cancer Research Nouveaux inducteurs puissants de differenciation de terminaisons et leur mode d'emploi
CH678394A5 (fr) * 1990-08-22 1991-09-13 Cerny Erich H
WO1993020064A1 (fr) * 1992-04-06 1993-10-14 Biosite Diagnostics Incorporated Nouveaux derives de barbituriques, conjugues et traceurs de derives de barbituriques fixes a des proteines et a des polypeptides
WO1998058925A1 (fr) * 1997-06-21 1998-12-30 Roche Diagnostics Gmbh Derives d'acide barbiturique dotes d'une activite antimetastatique et anitumorale

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003531196A (ja) 2000-04-24 2003-10-21 アリックス セラピューティクス 超短時間作用型催眠性バルビツール酸塩

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2405732A1 (de) * 1974-02-07 1975-08-21 Bayer Ag Ekto- und endoparasitenmittel
FR2300568A1 (fr) * 1975-02-17 1976-09-10 Spofa Vereinigte Pharma Werke Procede de preparation de nouveaux derives de l'acide 5-carboxyalcoyle-2-iminobarbiturique
US4634707A (en) * 1983-12-19 1987-01-06 Uniroyal Chemical Company 5-Pyrimidinecarboxamides and treatment of leukemia and tumors therewith
WO1991008191A1 (fr) * 1989-11-14 1991-06-13 Sloan-Kettering Institute For Cancer Research Nouveaux inducteurs puissants de differenciation de terminaisons et leur mode d'emploi
CH678394A5 (fr) * 1990-08-22 1991-09-13 Cerny Erich H
WO1993020064A1 (fr) * 1992-04-06 1993-10-14 Biosite Diagnostics Incorporated Nouveaux derives de barbituriques, conjugues et traceurs de derives de barbituriques fixes a des proteines et a des polypeptides
WO1998058925A1 (fr) * 1997-06-21 1998-12-30 Roche Diagnostics Gmbh Derives d'acide barbiturique dotes d'une activite antimetastatique et anitumorale

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
AL-AZHAR J. PHARM. SCI., vol. 17, 1996, CAIRO, pages 35 - 40 *
CHEMICAL ABSTRACTS, vol. 100, no. 28, 1984, Columbus, Ohio, US; abstract no. 68316w, page 603; column 1; XP002188339 *
CHEMICAL ABSTRACTS, vol. 126, no. 17, 1997, Columbus, Ohio, US; abstract no. 225269q, ABDEL-HAMIDE: "SYNTHESIS OF 2-[[[(5-ETHYL-5-PHENYL-1-BARBITURYL)METHYL]CARBONYL]THIO]Q" page 575; column 2; XP002188340 *
CHEMICAL ABSTRACTS, vol. 95, no. 7, 1981, Columbus, Ohio, US; abstract no. 54821y, TIWARI,S.: "SEARCH FOR CNS ACTIVE AGENTS:" page 42; XP002188341 *
CHEMICAL ABSTRACTS, vol. 97, no. 1, 1982, Columbus, Ohio, US; abstract no. 16559c, AL SHARIFI: "THE EFFECT OF ANTIAMOEBIC DRUG THERAPY ON THE METABOLISM OF BUTOBARBITONE." page 13; XP002047274 *
J.MIREK: "SYNTHESIS A. PHARMACOLOGICAL SCREENING OF SOME N-CARBOXYMETHYLBARBITURIC ACID DERIVATIVES 1.", POL. J. PHARMACOL., vol. 30, 1978, PL, pages 685 - 93, XP001053133 *
J.PHARM. PHARMACOL., vol. 34, no. 2, 1982, ENGL., pages 126 - 7 *
POL.J. PHARMACOL. PHARM., vol. 33, no. 1, 1981, PL, pages 115 - 120 *

Also Published As

Publication number Publication date
US6387914B2 (en) 2002-05-14
WO2001081319A2 (fr) 2001-11-01
JP2003531196A (ja) 2003-10-21
US20040167143A1 (en) 2004-08-26
AU2001257230B2 (en) 2006-09-14
US20020013330A1 (en) 2002-01-31
USRE41289E1 (en) 2010-04-27
US20030100575A1 (en) 2003-05-29
EP1276728A2 (fr) 2003-01-22
US7041673B2 (en) 2006-05-09
US6683086B2 (en) 2004-01-27
AU5723001A (en) 2001-11-07
CA2404898A1 (fr) 2001-11-01

Similar Documents

Publication Publication Date Title
AU2001234466A1 (en) Tunable indocyanine dyes for biomedical applications
EP1276738B8 (fr) Derives du 2-amino-3-(alkyl)-pyrimidone, inhibiteurs du gsk3$g(b)
WO2002020501A3 (fr) Polyarylcarboxamides utilises comme agents hypolipidemiants
FR2840903B1 (fr) Derive de glucose et de vitamine f, compositions le comprenant et utilisations pour ameliorer l'etat des poils et des cheveux
AU2001283512A1 (en) Methods for treating burns on mammalian skin to reduce the risk of infection andto minimize fluid loss
EP1454897A4 (fr) Derives de pyrazolopyrimidinone possedant une activite inhibitrice de pde7
AU2001262150A1 (en) 2-(nitrogen-heterocyclic)pyrimidone derivatives
AU2001288686A1 (en) Improved cardiac function through administration of es cells
WO2001081319A3 (fr) Barbituriques hypnotiques a action ultrabreve
AU2001240094A1 (en) Customized laser ablation of corneas with solid state lasers
AU2002212359A1 (en) Skin oils consisting of oil-soluble constituents
WO2003059875A3 (fr) Dérivés d'acides $g(a)-phénylthiocarboxylique et $g(a)-phényloxy-carboxylique convenant bien pour le traitement de maladies répondant à une activation de ppar$g(a)
BR0012169A (pt) Dihidrobenzodiazepinas e seu uso no tratamento de dislipidemia
AU2002227935A1 (en) Optical stimulation of the human eye
WO2001019826A3 (fr) Nouveaux composes
AU4719699A (en) Substituted quinoxalin-2(1h)-ones useful as hiv reverse transcriptase inhibitors
AU2001291744A1 (en) Arylpiperazine derivatives and their use as psychotropic agents
AU4503499A (en) Use of 2-(n-phenylamino)pyrimidines as fungicides, and novel 2-(n-phenylamino)pyrimidines
WO2004060281A3 (fr) Dérivés de 2-arylthiazole utilisés comme modulateurs de kcnq
AU2002230164A1 (en) Crystal of pyrimidine nucleoside derivative
AU5026600A (en) Methods of regulating the condition of mammalian keratinous tissue
WO2002038106A3 (fr) Composes calcilytiques
AU6878500A (en) Novel 2-(2-pyridyl)pyrimidine derivatives
AU3199099A (en) 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinthione derivatives, their preparation and their use as hiv reverse transcriptase inhibitors
IT1313660B1 (it) Procedimento stereoselettivo per la preparazione di endo-3-amminoazabicicloalcani.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2404898

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001257230

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 578413

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001930722

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001930722

Country of ref document: EP